Author
Bristol-Myers Squibb (United States)ORCID 0000-0002-6407-7344Unclaimed ORCID profile · follow to get notified of new preprints
3 papers
Recent·Most cited
Andres H. de la Peña, Justin T. Cruite, Jianwei Che…·Lyn H. Jones
The paper shows that covalent modification of CRBN by EM12-FS creates a new interface for NTAQ1 recruitment, expanding degrader specificity beyond the G-loop degron.
Edmond R. Watson, Scott J. Novick, Mary E. Matyskiela…·Gabriel C. Lander
This study investigates how CELMoD compounds induce conformational changes in cereblon, enabling neosubstrate binding and informing drug design strategies.
Gang Lu, Stephanie Weng, Mary E. Matyskiela…·Mark Rolfe
The paper identifies UBE2G1 as a critical E2 ubiquitin-conjugating enzyme required for the degradation of CRL4CRBN neomorphic substrates, showing its role in drug resistance and potential for overcoming it with next-generation compounds.